ProfileGDS5678 / 1437427_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 59% 58% 55% 59% 61% 62% 59% 59% 59% 59% 60% 59% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5919759
GSM967853U87-EV human glioblastoma xenograft - Control 23.5460859
GSM967854U87-EV human glioblastoma xenograft - Control 33.5083958
GSM967855U87-EV human glioblastoma xenograft - Control 43.3373655
GSM967856U87-EV human glioblastoma xenograft - Control 53.4950959
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7404461
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8061662
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5313659
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5248159
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5402659
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5395459
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5385960
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5431159
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5434359